Neutrophil Gelatinase-associated Lipocalin Concentration in Coronary Artery Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00749281|
Recruitment Status : Completed
First Posted : September 9, 2008
Last Update Posted : July 8, 2010
|Condition or disease|
|Coronary Artery Disease Atherosclerosis|
Inflammation is considered to play a major role in coronary artery disease (CAD) which accounts for high morbidity and mortality rates in the western world. Several lines of evidence support a role for neutrophils in the development of atherosclerosis and its progression.
Neutrophil gelatinase-associated lipocalin (NGAL), also known as Lipocalin-2, is a 25-kDa secretory glycoprotein that was originally identified in mouse kidney cells and human neutrophil granules. This protein has been used as a marker of neutrophil activation in several studies, while recently it was found to be an inflammatory marker closely related to obesity and its metabolic complications.
Recently, lactoferrin, a protein which co-localizes with NGAL in the specific granules of human neutrophils has been proposed as a more dynamic marker of neutrophil activation compared to the widely used myeloperoxidase in patients with CAD.
In line with the accumulating evidence, this study is designed to investigate the relationship between serum NGAL concentration and the presence or the severity of coronary artery disease according to coronary angiography.
|Study Type :||Observational|
|Actual Enrollment :||73 participants|
|Observational Model:||Case Control|
|Official Title:||Neutrophil Gelatinase-associated Disease: a Potential Biomarker of the Severity of Coronary Artery Disease|
|Study Start Date :||September 2008|
|Primary Completion Date :||March 2009|
|Study Completion Date :||September 2009|
Patients with angiographically confirmed significant CAD
Patients without significant CAD
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00749281
|Athens, Attica, Greece, 11521|
|Study Chair:||Demosthenes Katritsis, MD,PhD||Athens Euroclinic and Cardiovascular Research Society|